Related references
Note: Only part of the references are listed.Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders
Tikam Chand Dakal et al.
IMMUNOBIOLOGY (2020)
Prevalence ofPD-L1expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis
Ilaria Girolami et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
New pathways in immune stimulation: targeting OX40
Carolina Alves Costa Silva et al.
ESMO OPEN (2020)
Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions
Jennifer E. Beane et al.
NATURE COMMUNICATIONS (2019)
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Xin Hu et al.
NATURE COMMUNICATIONS (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
The Immune Revolution: A Case for Priming, Not Checkpoint
Robert H. Vonderheide
CANCER CELL (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling
Subhayan Sur et al.
CANCER PREVENTION RESEARCH (2018)
Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
David M. Woods et al.
CLINICAL CANCER RESEARCH (2018)
Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis.
Nassib William William et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions
Jin Wang et al.
CANCER PREVENTION RESEARCH (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Combined immune checkpoint targeting with anti-PD-1 plus anti-CD40 antibodies as the most effective approach to eradicate head and neck squamous cell carcinomas (HNSCCs) in mouse models
Jose Augusto Monteiro de Oliveira Novaes et al.
CANCER RESEARCH (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach
Marc D. Ryser et al.
CANCER RESEARCH (2016)
Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention
Jose Augusto Monteiro de Oliveira Novaes et al.
FUTURE ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
Athanasios Kotsakis et al.
SCIENTIFIC REPORTS (2016)
Erlotinib and the Risk of Oral Cancer The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial
William N. William et al.
JAMA ONCOLOGY (2016)
Regulatory circuits of T cell function in cancer
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Oral cavity and oropharyngeal squamous cell carcinomaan update
Angela C. Chi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
The clonal relationships between pre-cancer and cancer revealed by ultra-deep sequencing
Henry M. Wood et al.
JOURNAL OF PATHOLOGY (2015)
Novel Markers to Delineate Murine M1 and M2 Macrophages
Kyle A. Jablonski et al.
PLOS ONE (2015)
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
Kayoko Waki et al.
CANCER SCIENCE (2014)
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
Christian A. Bauer et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
Ilia N. Buhtoiarov et al.
IMMUNOLOGY (2011)
Dual Inhibition of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor is an Effective Chemopreventive Strategy in the Mouse 4-NQO Model of Oral Carcinogenesis
Guolin Zhou et al.
CANCER PREVENTION RESEARCH (2010)
Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk
Manuela Marron et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2010)
Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice
Shimpei Kasagi et al.
JOURNAL OF IMMUNOLOGY (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
A Dynamic Oral Cancer Field Unraveling the Underlying Biology and Its Clinical Implication
Ivy F. L. Tsui et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
ABT-510 Is an Effective Chemopreventive Agent in the Mouse 4-Nitroquinoline 1-Oxide Model of Oral Carcinogenesis
Rifat Hasina et al.
CANCER PREVENTION RESEARCH (2009)
Pilot randomized phase II study of celecoxib in oral premalignant lesions
Vassiliki A. Papaclimitrakopoulou et al.
CLINICAL CANCER RESEARCH (2008)
CD40 on APCs is needed for optimal programming, maintenance, and recall of CD8+ T cell memory even in the absence of CD4+ T cell help
Maria Genevive H. Hernandez et al.
JOURNAL OF IMMUNOLOGY (2008)
Forty mouse strain survey of water and sodium intake
Michael G. Tordoff et al.
PHYSIOLOGY & BEHAVIOR (2007)
CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help
Maria Genevive H. Hernandez et al.
JOURNAL OF IMMUNOLOGY (2007)
CD38 plays a role in effective containment of mycobacteria within granulomata and polarization of Th1 immune responses against Mycobacterium avium
Marta S. Viegas et al.
MICROBES AND INFECTION (2007)
4-nitroquinoline-1-oxide induced experimental oral carcinogenesis
Deepak Kanojia et al.
ORAL ONCOLOGY (2006)
CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity
GJD van Mierlo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection
L Zhang et al.
ORAL ONCOLOGY (2001)
Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand
K Murata et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
